Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 9/20 | 0.51 |
| ▸ | CYSLTR2 | Q9NS75 | 8/20 | 0.51 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
| ▸ | PPARG | P37231 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
| ▸ | XPO1 | O14980 | 1/20 | 0.39 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.39 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RARB | P10826 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4294287 | 0.93 | CYSLTR2 (0.53) | CYSLTR1CYSLTR2PLA2G4AEPHX2PPARG | |
| SCHEMBL8951187 | 0.91 | CYSLTR1 (0.50) | CYSLTR1CYSLTR2PLA2G4AEPHX2PPARG | |
| SCHEMBL6716972 | 0.91 | CYSLTR1 (0.50) | CYSLTR1CYSLTR2PLA2G4AEPHX2PPARG | |
| SCHEMBL9221477 | 0.90 | CYSLTR1 (0.46) | CYSLTR1CYSLTR2PLA2G4AEPHX2PPARG | |
| SCHEMBL8951325 | 0.88 | CYSLTR2 (0.51) | CYSLTR1CYSLTR2PLA2G4AEPHX2PPARG | |
| SCHEMBL8951557 | 0.88 | EPHX2 (0.52) | EPHX2MEN1CYP2C9KMT2A | |
| SCHEMBL8951482 | 0.88 | CYSLTR2 (0.49) | CYSLTR1CYSLTR2PLA2G4AEPHX2PPARG | |
| SCHEMBL8951115 | 0.88 | CYSLTR2 (0.52) | CYSLTR1CYSLTR2PLA2G4AEPHX2PPARG | |
| SCHEMBL8951235 | 0.88 | CYSLTR2 (0.52) | CYSLTR1CYSLTR2PLA2G4AEPHX2PPARG | |
| SCHEMBL8951265 | 0.87 | CYSLTR2 (0.53) | CYSLTR1CYSLTR2PLA2G4AEPHX2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170825-A2 | SUBSTITUTED INDOLES | Auspex Pharmaceuticals, Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20090191183-A1 | SUBSTITUTED INDOLES | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-07-30 | — | — | US | disclosed |
| WO-2009018280-A2 | SUBSTITUTED INDOLES | AUSPEX PHARAMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20090012146-A1 | SOLUBILITY-ENHANCED PHARMACEUTICAL COMPOSITIONS COMPRISING ZAFIRLUKAST | DR. REDDY'S LABORATORIES LIMITED (IN) | 2009-01-08 | — | — | US | disclosed |
| US-20040186300-A1 | Process for the preparation of zafirlukast | FINETECH LABORATORIES LTD. (IL) | 2004-09-23 | — | — | US | disclosed |
| WO-2002046153-A2 | PROCESS FOR THE PREPARATION OF ZAFIRLUKAST | FINETECH LABORATORIES LTD. (IL) | 2002-06-13 | — | — | WO | disclosed |
| US-5583152-A | Use of N-(4-(5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-ylmethyl)-3 -methoxybenzoyl)-2-methyl-benzenesulphonamide, zafirlukast; allergic asthma, inflammatory diseases, endotoxic conditions or traumatic shock | ZENECA INC. (US) | 1996-12-10 | — | — | US | disclosed |
| EP-0227241-B1 | Medicinal indole and indazole keto sulphone derivatives | ZENECA INC (US) | 1996-09-11 | — | — | EP | disclosed |
| US-5440035-A | Leukotriene antagonists; antiallergens, antiinflammatory agents | ZENECA INC. (GB) | 1995-08-08 | — | — | US | disclosed |
| US-5391758-A | Leukotriene antagonists | ZENECA, INC. (US) | 1995-02-21 | — | — | US | disclosed |
| US-5338734-A | Leukotriene antagonist properties; antiinflammatory agents | ZENECA INC. (US) | 1994-08-16 | — | — | US | disclosed |
| US-5179112-A | Leukotriene antagonist as antiallergens and antiinflammatory agents | ICI AMERICAS INC. (US) | 1993-01-12 | — | — | US | disclosed |
| EP-0199543-B1 | HETEROCYCLIC AMIDE DERIVATIVES | ICI AMERICAS INC. (US) | 1991-12-04 | — | — | EP | disclosed |
| US-5030643-A | Antiallergens, antiinflammatory agents | ICI AMERICAS INC. (US) | 1991-07-09 | — | — | US | disclosed |
| US-4859692-A | Heterocyclic amide derivatives and pharmaceutical use | ICI AMERICAS INC. (US) | 1989-08-22 | — | — | US | disclosed |
| US-4837235-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS | ICI AMERICAS INC. (US) | 1989-06-06 | — | — | US | disclosed |
| EP-0227241-A2 | Medicinal indole and indazole keto sulphone derivatives | ZENECA INC. (US) | 1987-07-01 | — | — | EP | disclosed |
| EP-0199543-A2 | Heterocyclic amide derivatives | ICI AMERICAS INC. (US) | 1986-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090191183-A1 | SUBSTITUTED INDOLES | CYSLTR1, LTB4R, LTB4R2 | CYSLTR1 1/4885CYSLTR2 4/4885PLA2G4A 144/4885 |
| US-20090012146-A1 | SOLUBILITY-ENHANCED PHARMACEUTICAL COMPOSITIONS COMPRISING ZAFIRLUKAST | PRSS3, PRSS1, PRSS2 | CYSLTR1 1940/4885CYSLTR2 1815/4885PLA2G4A 3283/4885 |
| US-20040186300-A1 | Process for the preparation of zafirlukast | LTC4S, LTB4R, CMA1 | CYSLTR1 15/4885CYSLTR2 32/4885PLA2G4A 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.